The chemical class referred to as MAPK1IP1L Activators encompasses a range of compounds that can activate the MAPK1IP1L protein, a component in the MAPK/ERK signaling pathway. These activators can initiate a cascade of events that lead to the modulation of MAPK1IP1L activity. The initiation usually begins at a receptor level, where ligands, such as growth factors, bind to receptor tyrosine kinases, which in turn trigger an intracellular signaling pathway involving phosphorylation events. This phosphorylation chain ultimately leads to the activation of MAPK1IP1L, as it is part of the intricate web of the MAPK/ERK pathway. The activators are not singular in their action but operate within the vast interconnectivity of cellular signaling networks. They serve as tools to manipulate specific signaling nodes that result in the activation of MAPK1IP1L, demonstrating the interconnected nature of cellular processes where altering one component can lead to changes in another.
The study and understanding of these activators rely on a deep knowledge of the MAPK/ERK pathway, as the activation of MAPK1IP1L is contingent on the proper functioning and regulation of this signaling route. Researchers utilize these activators to dissect the pathways, to understand the influence exerted by MAPK1IP1L within cellular contexts. This includes investigating how the activation of upstream components can lead to a series of phosphorylation events, and how these events can relay signals that result in the functional modulation of MAPK1IP1L. The precise mapping of these pathways allows for a clearer picture of the role MAPK1IP1L plays in cellular signaling. The activators serve as keys to unlock the mechanisms by which MAPK1IP1L can be regulated and are thus crucial in piecing together the signaling landscape where MAPK1IP1L is an integral component.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can lead to activation of the MAPK/ERK pathway and could activate MAPK1IP1L. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, another MAPK pathway, which could activate MAPK1IP1L through cross-talk with the ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, part of the MAPK family, and could activate MAPK1IP1L via interactions with the MAPK/ERK pathway. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, which increases cAMP levels and can lead to PKA activation; this could activate MAPK1IP1L through cross-talk with the MAPK/ERK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which can affect the MAPK/ERK pathway through cross-talk, and this could activate MAPK1IP1L. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in cellular growth and proliferation, and could activate MAPK1IP1L through indirect pathway interactions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that could affect MAPK1IP1L activity through its effects on downstream signaling pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate MAPK pathways as a stress response, which could activate MAPK1IP1L. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor, typically used as a therapeutic agent, which could be used to evaluate the modulation of MAPK1IP1L within the MAPK/ERK pathway. | ||||||